Atypical antidepressants are a pharmacological class defined by mechanisms of action that fall outside the SSRI, SNRI, TCA, and MAOI categories, yet still act on monoamine neurotransmission (serotonin, norepinephrine, dopamine) to treat major depressive disorder, a multifactorial mood disorder linked to decreased monoamine activity. Each agent is characterized by a distinct combination of reuptake inhibition, receptor agonism/antagonism, or receptor-subtype selectivity (e.g., alpha-2 antagonism, 5-HT2/5-HT3 antagonism, H1 antagonism, nicotinic acetylcholine partial agonism, 5-HT1A partial agonism), which determines both its therapeutic niche and its characteristic toxicity profile. This class illustrates the broader pharmacological principle that receptor- and transporter-level selectivity within a shared neurotransmitter system produces divergent clinical indications, side-effect profiles, and drug-interaction risks (notably serotonin syndrome) among agents nominally grouped together.
Atypical antidepressants are a pharmacological class defined by mechanisms of action that fall outside the SSRI, SNRI, TCA, and MAOI categories, yet still act on monoamine neurotransmission (serotoni…